Study: NCT05142696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: OTHER
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Intervention type: OTHER
Group type: OTHER
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period